This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.
Immunogen
This VHL antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 181-210 amino acids from the C-terminal region of human VHL.
Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.
Preservative
Sodium azide
Precaution of Use
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage
4 °C,-20 °C
Storage Comment
Maintain refrigerated at 2-8 °C for up to 6 months. For long term storage store at -20 °C in small aliquots to prevent freeze-thaw cycles.
Expiry Date
6 months
Li, Qu, Jin, Guo, Wang, Qi, Yang, Zhang, Li: "Protective effect of salidroside against bone loss via hypoxia-inducible factor-1α pathway-induced angiogenesis." in: Scientific reports, Vol. 6, pp. 32131, (2018) (PubMed).
Guo, Qi, Yang, Wang, Wang, Li, Li, Qu, Wang, Han: "Salidroside accelerates fracture healing through cell-autonomous and non-autonomous effects on osteoblasts." in: Cell and tissue research, Vol. 367, Issue 2, pp. 197-211, (2017) (PubMed).
Target
VHL
(Von Hippel-Lindau Tumor Suppressor, E3 Ubiquitin Protein Ligase (VHL))
Von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumors. A germline mutation of VHL gene is the basis of familial inheritance of VHL syndrome. The protein is a component of the protein complex that includes elongin B, elongin C, and cullin-2, and possesses ubiquitin ligase E3 activity. This protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF), which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. RNA polymerase II subunit POLR2G/RPB7 is also reported to be a target of this protein.